Navigation Links
NASDAQ Panel Grants Merge Technologies Additional Time to Regain Compliance
Date:11/1/2007

MILWAUKEE, Nov. 1 /PRNewswire-FirstCall/ -- Merge Technologies Incorporated, d.b.a. Merge Healthcare (Nasdaq: MRGE; TSX: MRG), today announced that the Company received a written notification from the NASDAQ Listing Qualifications Panel stating that the panel determined to continue the listing of the Company's common stock on The NASDAQ Stock Market subject to the Company's filing of its Form 10-Q for the quarter ended June 30, 2007 by no later than January 29, 2008. As indicated in the Company's news release dated October 29, 2007, the Company currently expects to file, on or before December 31, 2007: (i) its restated audited financial statements for the years ended December 31, 2004, 2005 and 2006, as well as other restated financial information previously included in the Company's Annual Report on Form 10-K for the year ended December 31, 2006, (ii) its restated unaudited financial statements included in its Quarterly Report on Form 10-Q for the quarter ended March 31, 2007, and (iii) its unaudited Quarterly Reports on Form 10-Q for the quarters ended June 30, 2007 and September 30, 2007.

(Logo: http://www.newscom.com/cgi-bin/prnh/20030430/MRGELOGO)

Merge Healthcare is a market leader in the development and delivery of medical imaging and information management software and services. Our innovative software solutions use leading-edge imaging software technologies that accelerate market delivery for our OEM customers, while our end-user solutions improve our customers' productivity and enhance the quality of patient care they provide. For additional information, visit our website at http://www.mergehealthcare.com.

All trademarks appearing in this release are the property of Cedara Software Corp. and/or Merge Healthcare.

Cautionary Notice Regarding Forward-Looking Statements

This announcement may include forward-looking statements within the meaning and subject to the protections of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, as amended. When used in this announcement, the words "will," "believes," "intends," "anticipates," "expects" and similar expressions of the future are intended to assist you in identifying such forward-looking statements. Such forward-looking statements include, among others, statements regarding the timing of our completion of our restatements and filings of related SEC reports.

Any number of factors could cause the actual timing or results to differ from the results contemplated by such forward-looking statements, including, but not limited to: the restatement may take longer to complete than expected; the Company's inability to timely file reports with the Securities and Exchange Commission; risks associated with the Company's inability to meet the requirements of The NASDAQ Stock Market for continued listing, including possible delisting; risks and effects of the past and current restatement of financial statements of the Company and other actions that may be taken or required as a result of such restatement; costs, risks and effects of legal proceedings and investigations, including the formal investigation being conducted by the Securities and Exchange Commission and class action, derivative, and other lawsuits; the uncertainty created by and the adverse impact on relationships with customers, potential customers, suppliers and investors potentially resulting from, and other risks associated with, the changes in the Company's senior management; and other risk factors detailed in the Company's filings with the Securities and Exchange Commission.

You should not place undue reliance on forward-looking statements, since the statements speak only as of the date that they are made. We do not have, or undertake any obligation to, publicly update, revise or correct any of the forward-looking statements after the date of this announcement, or after the respective dates on which such statements otherwise are made, whether as a result of new information, future events or otherwise. This announcement should be read in conjunction with the risk factors, financial information and other information contained in the filings that the Company makes and previously has made with the Securities and Exchange Commission.


'/>"/>
SOURCE Merge Technologies Incorporated
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. NASDAQ will continue to list Merge
2. NASDAQ grants Merge more time for compliance
3. NASDAQ will continue to list Merge
4. No word on NASDAQ extension for Merge
5. NASDAQ puts Merge on notice again
6. Flat panel displays
7. Panel stresses drawing outside biotech firms to state
8. National stem-cell panel, including UW profs, urges close watch on research
9. Star panel re-evaluates Sarbanes-Oxley one year in at SEC headquarters
10. Distance Education Conference Selects Sonic Foundry to Make Keynotes, Panel Presentations Available On-Demand
11. State to offer $850K in high-tech training grants
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... - FACIT has announced the creation of a ... Propellon Therapeutics Inc. ("Propellon" or "the Company"), to ... of first-in-class WDR5 inhibitors for the treatment of ... an exciting class of therapies, possessing the potential ... patients. Substantial advances have been achieved with the ...
(Date:6/23/2016)... Prostate Cancer Foundation (PCF) is pleased to announce 24 new Young Investigator ... Members of the Class of 2016 were selected from a pool of 128 ... About the Class of 2016 PCF Young Investigators ... ... ...
(Date:6/23/2016)... ... , ... STACS DNA Inc., the sample tracking software company, today announced that ... joined STACS DNA as a Field Application Specialist. , “I am thrilled that ... of STACS DNA. “In further expanding our capacity as a scientific integrator, Hays brings ...
(Date:6/23/2016)... , June 23, 2016 ... Hematology Review, 2016;12(1):22-8 http://doi.org/10.17925/OHR.2016.12.01.22 ... , the peer-reviewed journal from touchONCOLOGY, Andrew ... escalating cost of cancer care is placing an ... result of expensive biologic therapies. With the patents ...
Breaking Biology Technology:
(Date:4/28/2016)... First quarter 2016:   , Revenues amounted to ... of 2015 The gross margin was 49% (27) ... operating margin was 40% (-13) Earnings per share rose ... was SEK 249.9 M (21.2) , Outlook   ... The operating margin for 2016 is estimated to exceed ...
(Date:4/15/2016)... -- A new partnership announced today will help life ... a fraction of the time it takes today, ... insurance policies to consumers without requiring inconvenient and ... rapid testing (A1C, Cotinine and HIV) and higi,s ... pulse, BMI, and activity data) available at local ...
(Date:3/31/2016)... 31, 2016   ... the "Company") LegacyXChange is excited to release ... soon to be launched online site for trading 100% ... ) will also provide potential shareholders a sense of ... to an industry that is notorious for fraud. The ...
Breaking Biology News(10 mins):